Search Within

Gottfried Von Keudell

Formats
  1. Meeting Abstract (30)
  2. Journal Article (14)
  3. Review (6)
  4. Correspondence (3)
  5. Editorial (1)
Groups
  1. CTCR Scholars (54)
  2. Department of Medicine (54)
  3. Hematologic Malignancies, Division of (54)
  4. MSK Grad Students (54)
  5. Master of Science in Clinical and Translational Cancer Research (54)
  6. Center for Hematologic Malignancies (44)

More Groups

People
  1. Andrew Zelenetz (31)
  2. Matthew Matasar (30)
  3. Alison Moskowitz (29)
  4. Ariela Noy (29)
  5. Erel Joffe (29)
  6. Connie Batlevi (28)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (8)
  4. 2021 (17)
  5. 2020 (12)
  6. 2019 (14)
Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (6)
  3. Hematological Oncology (4)
  4. Leukemia and Lymphoma (4)
  5. Blood Advances (3)
  6. Blood Cancer Journal (3)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (4)
  4. Taylor & Francis Group (4)
  5. Wiley Blackwell (4)
  6. Elsevier Inc. (2)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma
    Journal Article

    Machino, H.; Kaneko, S.; Komatsu, M.; Ikawa, N.; Asada, K.; Nakato, R.; Shozu, K.; Dozen, A.; Sone, K.; Yoshida, H.; more...
    Communications Biology (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Ansell, S.; Bröckelmann, P.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G.; Cohen, J.; De Boer, J. P.; Kuruvilla, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save